IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11679107 B1

PDFFull Text
Date of Patent:
Jun. 20, 2023

Filed:

Apr. 11, 2019

Certain aryl pladienolide compounds and methods of use

Applicant:

Eisai R&d Management Co., Ltd., Tokyo, JP;

Inventors:

Andrew Cook, Stow, MA (US);

Dominic Reynolds, Stoneham, MA (US);

Cheng Zhong, Belmont, MA (US);

Ryan Brawn, Sudbury, MA (US);

Shelby Ellery, Boston, MA (US);

Thiwanka Samarakoon, Westwood, MA (US);

Xiang Liu, Winchester, MA (US);

Sudeep Prajapati, Somerville, MA (US);

Megan Sheehan, Allston, MA (US);

Jason T. Lowe, East Bridgewater, MA (US);

James Palacino, Wellesley, MA (US);

Assignee:

EISAI R&D MANAGEMENT CO., LTD., Tokyo, JP;

Attorney:

Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

Primary Examiner:

Jeffrey H Murray

Int. Cl.
CPC ...
C07D 405/06 (2006.01); A61K 31/496 (2006.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01); A61K 31/497 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61K 31/5386 (2006.01); A61K 31/541 (2006.01); A61K 31/551 (2006.01); A61K 38/19 (2006.01); A61K 38/20 (2006.01); A61K 38/21 (2006.01); A61K 39/395 (2006.01); C07D 313/00 (2006.01); C07D 405/10 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01); C07D 407/12 (2006.01); C07D 409/12 (2006.01); C07D 413/10 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 417/10 (2006.01); C07D 453/02 (2006.01); C07D 471/10 (2006.01); C07D 487/04 (2006.01); C07D 491/107 (2006.01); C07D 498/08 (2006.01);
U.S. Cl.
CPC ...
A61K 31/496 (2013.01); A61K 9/0053 (2013.01); A61K 31/497 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 31/5386 (2013.01); A61K 31/541 (2013.01); A61K 31/551 (2013.01); A61K 38/191 (2013.01); A61K 38/208 (2013.01); A61K 38/2013 (2013.01); A61K 38/2066 (2013.01); A61K 38/2086 (2013.01); A61K 38/217 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); C07D 313/00 (2013.01); C07D 405/06 (2013.01); C07D 405/10 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 407/12 (2013.01); C07D 409/12 (2013.01); C07D 413/10 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/10 (2013.01); C07D 453/02 (2013.01); C07D 471/10 (2013.01); C07D 487/04 (2013.01); C07D 491/107 (2013.01); C07D 498/08 (2013.01); C07B 2200/05 (2013.01);
Abstract

The present disclosure provides pladienolide compounds, pharmaceutical compositions containing such compounds, and pladienolide compounds for use in methods of medical treatment. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are pladienolide compounds for use in methods of treating cancers by administering at least one pladienolide compound disclosed herein and at least one additional therapy

Find Patent Forward Citations

Loading…